Whooping Cough Clinical Trial
Official title:
An Observational, Retrospective Cohort Database Study to Assess the Safety of Boostrix (U.S. Formulation), a Reduced Tetanus, Diphtheria, Acellular Pertussis Vaccine (Tdap), Following Routine Immunization of Pregnant Women in the United States
The purpose of this study was to assess the safety of Boostrix administered on or after the first day of the 27th week of pregnancy by conducting a post-marketing study that provided safety information to the public and healthcare providers. This was one of the largest cohorts of pregnant women vaccinated with Boostrix in the U.S. Through partnership between Kaiser Permanente Southern California (KPSC) and the sponsor, GlaxoSmithKline (GSK), information about the safety of maternal vaccination with Boostrix and maternal and infant adverse events (AEs) in a community setting was gained.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03035370 -
Viaskin Pertussis Vaccine Trial
|
Phase 1 | |
| Completed |
NCT02453048 -
Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine
|
Phase 1 | |
| Completed |
NCT01444781 -
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
|
Phase 3 | |
| Active, not recruiting |
NCT05091619 -
A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
|
Phase 3 | |
| Completed |
NCT02587520 -
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects
|
Phase 1/Phase 2 | |
| Completed |
NCT01983540 -
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination
|
Phase 3 | |
| Completed |
NCT01545115 -
Study of the Environmental Factors Modulating Children Immune Response in Northern Senegal
|
N/A | |
| Recruiting |
NCT04238975 -
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults
|
Phase 2 | |
| Completed |
NCT01439165 -
Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose
|
Phase 4 | |
| Recruiting |
NCT03751514 -
Bordetella Pertussis Colonisation Challenge Study
|
N/A | |
| Active, not recruiting |
NCT01279668 -
Montelukast for Persistent Cough in Young People and Adults
|
Phase 4 | |
| Completed |
NCT00337428 -
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)
|
Phase 3 | |
| Completed |
NCT00662870 -
Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine
|
Phase 3 | |
| Completed |
NCT01529645 -
Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years
|
Phase 1 | |
| Recruiting |
NCT04036526 -
A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02813486 -
Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine
|
Phase 1/Phase 2 | |
| Completed |
NCT01629589 -
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
|
Phase 4 | |
| Completed |
NCT03942406 -
Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults
|
Phase 2 | |
| Completed |
NCT03137927 -
A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine
|
Phase 1 | |
| Completed |
NCT02301702 -
Maternal Tdap Immunization in Guatemala
|
Phase 2 |